Trial Profile

A Phase 2, Open-Label, Single-Center Study of MTG201 in Combination With Nivolumab in Patients With Relapsed Malignant Pleural Mesothelioma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary) ; Nivolumab (Primary)
Indications Malignant-mesothelioma
Focus Therapeutic Use
Sponsors Momotaro-Gene

Most Recent Events

13 Jun 2022 Planned End Date changed from 20 Dec 2021 to 1 Jan 2023.
13 Jun 2022 Planned primary completion date changed from 20 Sep 2020 to 31 Dec 2022.
13 Jun 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com